Welcome to our dedicated page for Astellas Pharma news (Ticker: ALPMY), a resource for investors and traders seeking the latest updates and insights on Astellas Pharma stock.
Astellas Pharma Inc. news covers developments from a Japanese pharmaceutical company and its unsponsored ADR, including oncology data, licensing activity, research collaborations and patient-focused programs. Recurring updates include clinical presentations for approved cancer therapies such as XTANDI with Pfizer, oncology pipeline additions such as the clinical-stage antibody-drug conjugate XNW27011, and collaborations that support drug-discovery startups in Japan, Korea and U.S. life-science incubators.
Company announcements also address patient advocacy initiatives, research-center and incubator access through programs such as SakuLab™-Tsukuba, and business-development agreements that expand Astellas' therapeutic and technology capabilities.
Astellas Pharma has released findings from two studies and a sleep survey that highlight the prevalence of vasomotor symptoms (VMS) during menopause and their disruptive effects on sleep. Approximately 34% of postmenopausal women in the U.S. experience moderate-to-severe VMS, with 61% reporting sleep disturbances. The studies underscore the need for new treatment options for VMS, given their negative impact on women's quality of life. These findings will be presented at the North American Menopause Society's 2020 Virtual Annual Meeting.
Astellas Pharma and Seattle Genetics announced that their phase 3 trial of PADCEV (enfortumab vedotin-ejfv) achieved its primary endpoint, demonstrating a significant improvement in overall survival for patients with locally advanced or metastatic urothelial cancer compared to chemotherapy. Specifically, the trial showed a 30% reduction in the risk of death (HR=0.70; p=0.001) and a 39% reduction in the risk of disease progression (HR=0.61; p0.00001). Results will be submitted to the FDA for confirmatory approval and are intended to support global registrations.